ACON
Aclarion
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 1
Revenue Plunges
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About ACON
Aclarion, Inc.
A healthcare technology company that develops software application for magnetic resonance spectroscopy (MRS) in the US
Life Science Tools and Services
Invalid Date
04/22/2022
NASDAQ Stock Exchange
6
12-31
Common stock
8181 Arista Place, Suite 100, Broomfield, Colorado 80021
--
Aclarion, Inc., was incorporated in Delaware in February 2015. The company is a healthcare technology company that utilizes magnetic resonance spectroscopy, and proprietary biomarkers to optimize clinical treatments. Aclarion's technology addresses the US $134.5B lower back and neck pain market, which is now the most expensive healthcare disease in the US, according to a 2020 JAMA article. The company is currently utilizing artificial intelligence to assist quality control processes that flag spectral data that indicate poor MRS research. The use of AI in this application is early in its development cycle and is expected to evolve with further research and development.
Company Financials
EPS
ACON has released its 2023 Q3 earnings. EPS was reported at -1.92, versus the expected -0.09, missing expectations. The chart below visualizes how ACON has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ACON has released its 2024 Q3 earnings report, with revenue of 14.41K, reflecting a YoY change of -24.43%, and net profit of -1.37M, showing a YoY change of -36.89%. The Sankey diagram below clearly presents ACON’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
